We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$495M
AUM Growth
-$74.9M
Cap. Flow
+$18.8M
Cap. Flow %
3.8%
Top 10 Hldgs %
58.78%
Holding
54
New
6
Increased
19
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$20.8M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$18.4M
3
ASND icon
Ascendis Pharma A/S
ASND
+$9.99M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$9.26M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$6.92M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$17.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$14.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$7.92M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$7.17M
5
BMY icon
Bristol-Myers Squibb
BMY
+$6.28M

Sector Composition

Rank Sector Weight
1 Healthcare 81.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CEMP
51
DELISTED
Cempra, Inc.
CEMP
– –
-30,000
Closed -$726K
INNL
52
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
– –
-468,148
Closed -$2.72M
OMED
53
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-85,000
Closed -$972K
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Avoro Capital Advisors held 54 positions worth $495M, down 13% from $570M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Avoro Capital Advisors deployed $18.8M of net new capital in Q4 2016, opening 6 new positions and adding to 19 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 170,000 shares worth $20.8M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $14.4M trimmed.

  • Avoro Capital Advisors's largest Q4 2016 buy was Alexion Pharmaceuticals: 170,000 shares worth $20.8M.
  • Avoro Capital Advisors added most to Acadia Pharmaceuticals in Q4 2016, an estimated $18.4M increase.
  • Avoro Capital Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $14.4M.
  • Avoro Capital Advisors fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2016, selling an estimated $17.7M.
  • Avoro Capital Advisors's ten largest holdings make up 59% of its $495M portfolio in Q4 2016.
  • Avoro Capital Advisors opened 6 new positions and closed 11 in Q4 2016.
  • Avoro Capital Advisors's portfolio value fell 13% quarter-over-quarter to $495M.

Based on Avoro Capital Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.